NCT03915964 and NCT04086745 have yet to report. Primary completion date of trial was May 2025. Nearly 4k randomized patients followed multiple years assessing JAKi safety. Potential release this month. #baricitinib bsky.app/profile/fipc...

"Pancreatic cancer mRNA vaccine shows lasting results in an early trial: Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later."

💬 Editorial: Simulation modeling demonstrates #ApoB-guided statin intensification is cost-effective, identifies more clinically meaningful risk, and aligns with 2026 ACC/AHA guidelines. ja.ma/4cxddfa

A computer simulation found #ApoB-guided intensification of lipid-lowering therapy provides the most QALYs and is highly cost-effective compared to #LDL-C or #nonHDL-C targets. ja.ma/4cxfzKX

New mega-analysis showing statin therapy is associated with reduced risk of AD and related out comes, pubmed.ncbi.nlm.nih.gov/41761642/ @nationallipid.bsky.social @aspcardio.bsky.social @fabyollaveras.bsky.social @menopausesociety.bsky.social @eassociety.bsky.social

Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume? Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky

Ann Marie Navar has more to say on this topic: youtu.be/DRO5kHfcnz0?...

AHA/ACC/+ Lipid Guidelines - another notable and welcome change: use of long term risk to guide lipid lowering therapy. 30-year PREVENT-ASCVD risk >=10% support use of lipid lowering therapy. (this adds a large number of 30-59yr olds over prior PCE 5%) x.com/fipco/status...

ApoB recommendations from the 2026 AHA/ACC/+ lipid guidelines. "reasonable to measure" Yay! /1 www.jacc.org/doi/full/10....

In Novo's head to head trial of Cagrisema 2.4/2.4mg compared to Tirzepatide 15mg, Cagrisema did not show non-inferiority on the primary endpoint of weight loss at 84 weeks. ITT weight loss 20.2% v 23.6%, PP 23.0% v 25.5% for C-S v T. REDEFINE-4 www.novonordisk.com/news-and-med...

"Recent research suggests that more people should be screened for a protein called apoB. A growing number of doctors agree." #cardiosky www.nbcnews.com/health/heart...

Rehman, et al. propose a single risk measure to reflect risk from apoB generally, Lp(a), and TG rich-lipoproteins. "RW-apoB" for "risk weighted". The scale is comparable to current apoB levels. #cardiosky /1 academic.oup.com/eurheartj/ad...

New online! Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies #CardioSky

A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks. Mild dysesthesias noted #weightloss #arthritis investor.lilly.com/news-release...

Open to views of others. I'm hooked based on RCT + supportive trial + limited alternatives. I'm also a supporter of high dose EPA for secondary CV prevention. That's based in part on theory that high achieved EPA drives benefit. That doesn't apply to PISCES... /1 bsky.app/profile/neph...

According to clinicaltrials.gov the baricitinib CV safety trials completed 6 months ago. Perhaps more t's to cross and i's to dot. This EULAR consensus review pointed to these studies as important in assessing JAKi safety. pubmed.ncbi.nlm.nih.gov/36357155/ bsky.app/profile/fipc...

The Economist on apoB. ApoB is inexpensive and more accurate than LDL-C. The measures disagree in 30-40% of individuals. www.economist.com/science-and-... #cardiosky

Thoughtful, provocative editorial. Some fair points. Respectfully disagree with apoB/CAC examples. IMO evidence base (including health economics) for these support broader use and are incorporated in some guidelines (apoB: EAS/ESC, CCS, NLA statement) #cardiosky bsky.app/profile/jame...

Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. #KidneyWK @asnkidney.bsky.social ja.ma/4oV4DtU

Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk Simultaneous pub in NEJM www.nejm.org/doi/full/10....

The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis www.nephjc.com/news/2025/10...

• start prevention earlier (than current guidelines suggest) • measure apoB Editorial by Angela Pirillo and Alberico Catapano #cardiosky academic.oup.com/eurheartj/ad...

ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...

NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky

"This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P." Analysis of UK Biobank data by Elizabeth Epstein, et al. #cardiosky pubmed.ncbi.nlm.nih.gov/40887080/

Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al. jamanetwork.com/journals/jam...

Lp(a) testing is highly cost effective (cost saving) in this study by Morton, et al. Applies to US and various other countries. #cardiosky #lpa #cea www.sciencedirect.com/science/arti...

Somewhat lukewarm view of colchicine in this editorial. "the CLEAR SYNERGY results have brought considerable clinical equipoise for the prescription of colchicine to reduce ASCVD risk" pubmed.ncbi.nlm.nih.gov/40825059/

From #T2D to #obesity #CVD #OSA and now #MASH The expanding benefits of GLP-1 medicines www.novonordisk.com/news-and-med...

This "living" guideline document will unlive many people with diabetes if applied. Why are guideline ppl addicted to sulfunylureas/nsulin/metformin ? Those are useful to lower A1c from stratospheric levels, but if we are thinking hard outcomes improvement, the answer is #flozin & #glp1 #fail

Orforglipron notches double digit #weightloss investor.lilly.com/news-release...

SURPASS CVOT #T2D #Tirzepatide Non inferior but numerically superior for some endpoints #CVD investor.lilly.com/news-release...

Looking below the surface... PREVENT equations seem better calibrated vs PCE in other studies compared to recent JACC study. VA, Kaiser, UK Biobank (ex-US), and others. /1 bsky.app/profile/fipc...

On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45. bsky.app/profile/pnat...

In Norway🇳🇴, 4 years after DAPA-HF, 85% of those with reduced ejection fraction heart failure get an SGLT2i. In the US🇺🇸, it's under 30%. #gdmt #flozins #cardiosky www.hcplive.com/view/study-h... onlinelibrary.wiley.com/doi/10.1002/...

A detailed look at dosing, efficacy and tolerability for Amycretin www.thelancet.com/journals/lan... #weightloss #obesity

Good interview with @danieljdrucker.bsky.social on obesity medicines. I clicked the translate button since hablo muy poco español elpais.com/salud-y-bien...

Three views on GIP agonism and antagonism. Thread with 3 links. #obesity #cardiosky bsky.app/profile/dani...

Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky www.lipidjournal.com/article/S193...

Mid-sized 🇬🇷discordance study (n=3042, 20 year follow-up) favors apoB over traditional lipid measures. By Giannakopoulou et al. /1 #cardiosky pubmed.ncbi.nlm.nih.gov/40386959/

Merck's enlicitide, an oral PCSK9i, meets LDL-C and other endpoints in 2 phase 3 trials. Details to come. "There were no clinically meaningful differences in incidences of AEs and SAEs in either trial" #cardiosky www.merck.com/news/merck-a... bsky.app/profile/fipc...

Pooled Cohort Equations and newer PREVENT 10 year risk equations won't identify many of those who had early MIs. #cardiosky pmc.ncbi.nlm.nih.gov/articles/PMC...

Related editorial by Sniderman et al. #apoB #Lp(a) #cardiosky academic.oup.com/eurheartj/ad... bsky.app/profile/eric...

SURMOUNT-5 Among participants with #obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72 www.nejm.org/doi/full/10....

With an editorial from the expert, Dr. Alice E. Adriaenssens @cambridgeuni.bsky.social disentangling divergent neural networks that explain the success of both GIPR gain and loss of function strategies for promoting #weightloss #obesity @naturemetabolism.bsky.social www.nature.com/articles/s42...

Best lab assessment for coronary artery risk consists of ApoB particles and LP(a) academic.oup.com/eurheartj/ad...

Soap opera of KETO-CTA study continues. Revision of paper expected per last author Budoff. Another cohort NATURE-CT with similar demographics - age, no statin - had ~1/4 the non-calcified plaque progression of the keto group 4.9 v 18.8. bsky.app/profile/fipc...

Lilly provides top line results of oral GLP-1 orforglipron phase 3 study ACHIEVE-1 in type 2 diabetics. At top dose, 1.5% ⬇️ HbA1c, 7.9% weight loss from baseline at 40 weeks. (efficacy estimand) No liver safety signal noted. #cardiosky bsky.app/profile/fipc... investor.lilly.com/news-release...

Another good summary of the KETO-CTA study. alexleaf.com/lean-mass-hy...

"majority [had] minimal progression"- co-author of KETO-CTA study. The values in Figure 1 for non-calcified plaque imply a 50% increase in median at 1 year. Big ⬆️'s in many w/ CAC=0. Nakanishi paper suggests annual increase in non-diabetics of 2.8 mm^3. bsky.app/profile/shoa...